Cargando…

New perspective in heart failure management: could myosin activators be the answer?

Heart failure is a worldwide leading cause of hospital admissions. There is a critical need for new methods of management in acute heart failure. The current drug panel available in the treatment of hemodinamically unstable patients is not only limited, but it is also associated with deleterious sid...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrei, Stefan, Iorgoveanu, Corina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Applied Systems srl 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941581/
https://www.ncbi.nlm.nih.gov/pubmed/32309560
http://dx.doi.org/10.15190/d.2014.25
_version_ 1783484568104337408
author Andrei, Stefan
Iorgoveanu, Corina
author_facet Andrei, Stefan
Iorgoveanu, Corina
author_sort Andrei, Stefan
collection PubMed
description Heart failure is a worldwide leading cause of hospital admissions. There is a critical need for new methods of management in acute heart failure. The current drug panel available in the treatment of hemodinamically unstable patients is not only limited, but it is also associated with deleterious side effects. Discoveries in the heart failure field seemed to lack an adequate answer and a change in paradigm may be necessary. The cardiac myosin activator omecamtiv mecarbil is a new therapeutic approach that improves the myocardial contractility through an innovative mechanism, avoiding the harmful effects of currently used inotropic agents. Several studies provided us with promising results, but further scientific proofs are needed.
format Online
Article
Text
id pubmed-6941581
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Applied Systems srl
record_format MEDLINE/PubMed
spelling pubmed-69415812020-04-17 New perspective in heart failure management: could myosin activators be the answer? Andrei, Stefan Iorgoveanu, Corina Discoveries (Craiova) Perspective Article Heart failure is a worldwide leading cause of hospital admissions. There is a critical need for new methods of management in acute heart failure. The current drug panel available in the treatment of hemodinamically unstable patients is not only limited, but it is also associated with deleterious side effects. Discoveries in the heart failure field seemed to lack an adequate answer and a change in paradigm may be necessary. The cardiac myosin activator omecamtiv mecarbil is a new therapeutic approach that improves the myocardial contractility through an innovative mechanism, avoiding the harmful effects of currently used inotropic agents. Several studies provided us with promising results, but further scientific proofs are needed. Applied Systems srl 2014-12-31 /pmc/articles/PMC6941581/ /pubmed/32309560 http://dx.doi.org/10.15190/d.2014.25 Text en Copyright © 2014, Applied Systems http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Perspective Article
Andrei, Stefan
Iorgoveanu, Corina
New perspective in heart failure management: could myosin activators be the answer?
title New perspective in heart failure management: could myosin activators be the answer?
title_full New perspective in heart failure management: could myosin activators be the answer?
title_fullStr New perspective in heart failure management: could myosin activators be the answer?
title_full_unstemmed New perspective in heart failure management: could myosin activators be the answer?
title_short New perspective in heart failure management: could myosin activators be the answer?
title_sort new perspective in heart failure management: could myosin activators be the answer?
topic Perspective Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941581/
https://www.ncbi.nlm.nih.gov/pubmed/32309560
http://dx.doi.org/10.15190/d.2014.25
work_keys_str_mv AT andreistefan newperspectiveinheartfailuremanagementcouldmyosinactivatorsbetheanswer
AT iorgoveanucorina newperspectiveinheartfailuremanagementcouldmyosinactivatorsbetheanswer